Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03746041 · ClinicalTrials.gov registry record · Phase 1
A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes
A Phase 1 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT03746041 is a Phase 1 study that has completed, run by University of Rochester. The registered enrollment target is 20 participants.
The verdict
NCT03746041, a Phase 1 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the safety and tolerability of combined abaloparatide and bevacizumab in patients with Myelodysplastic Syndromes (MDS). A secondary objective is to determine the response to treatment (based on bone marrow and peripheral blood findings). A tertiary objective is to determine the impact of therapy on health-related quality of life (HRQOL) and patient-reported outcomes (PRO). A quaternary (scientific) objective is to determine the impact of treatment on both hematopoietic and stromal cell populations within the bone marrow of MDS patients.
Interventions
- DRUG bevacizumab
- DRUG abaloparatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-02-14 |
| Est. Completion | 2022-06-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03746041
The ClinicalTrials.gov registry entry for NCT03746041 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which bevacizumab is the first listed.
NCT03746041 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03746041 about?
NCT03746041 is a clinical study titled "A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes". The primary objective of this study is to determine the safety and tolerability of combined abaloparatide and bevacizumab in patients with Myelodysplastic Syndromes (MDS). A secondary objective is to determine the response to treatment (based on bone marrow and peripheral blood findings). A tertiary...
What is the current status of trial NCT03746041?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2019-02-14. Estimated completion is 2022-06-06.
What interventions are being tested in trial NCT03746041?
The interventions under investigation include: bevacizumab (DRUG), abaloparatide (DRUG).
Who is sponsoring clinical trial NCT03746041?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.